Molecular Match
Molecular Match is a Houston-based private health technology company founded in 2014, operating in cancer treatment with a small team and a molecular-matching focus. It has raised approximately $6.36 million across five rounds through 2016, primarily from Houston Angel Network.
- Company typePrivate
- Founded2014
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Molecular Match does
Molecular Match is a Houston, Texas-based private health technology company founded in 2014, operating with a small team (11-50 employees) in the cancer treatment domain. Its name and category positioning suggest it focuses on molecular-level matching — connecting cancer patients, treatments, or clinical options through its platform — though the company-specific value proposition, core product surface, and underlying technical architecture are not disclosed in the available source data. The company is led by co-founder/CTO Nick Tackes, founder/CMO James Welsh, and CFO Greg Guidroz.
The company has raised approximately $6.36 million across five disclosed funding rounds between March 2014 and January 2016, with the largest single round being a $5.2 million Series 1 in March 2014. Investors are predominantly Houston Angel Network and UT Horizon Fund, indicating a Houston-anchored, locally-sourced capital base with no disclosed institutional venture participation. No subsequent funding, acquisitions, partnerships, product launches, or geographic expansions have been disclosed in the available source material.
The business model, pricing, customer segments, GTM motion, and revenue mechanics are not described in the input data, representing a material data gap. The company operates within the broader AI-in-genomics market context, which is projected to reach $9.32 billion by 2030 at a 43.7% CAGR, providing a favorable secular backdrop for any precision-oncology or molecular-matching venture, though Molecular Match's specific commercial traction and product adoption cannot be verified from the available data.
Molecular Match firmographics
Firmographics- Name
- Molecular Match
- Website
- https://molecularmatch.com
- Company type
- Private
- Founded year
- 2014
- Headcount range
- 11–50 employees
- Short description
- Molecular Match is a Houston-based private health technology company founded in 2014, operating in cancer treatment with a small team and a molecular-matching focus. It has raised approximately $6.36 million across five rounds through 2016, primarily from Houston Angel Network.
- Ownership category
- akta.pro rank
Molecular Match industry classification
Industry- Product category
- Precision Oncology Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)
- akta.pro secondary industry
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)
Keywords
Where Molecular Match is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Markets served
Molecular Match business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations
Molecular Match product offering
Product offeringCore offering
Molecular Match is a health and wellness company that develops technology for cancer treatment, leveraging molecular-level data to support treatment matching and decision-making. The company operates within the AI-driven genomics and precision medicine space, serving healthcare organizations involved in oncology care.
Differentiator
Problem solved
Functional benefit
Companies that use Molecular Match
Customer profileIdeal customer profiles1 record
Molecular Match technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Molecular Match partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights1 record
Molecular Match competitors and assessment
Company assessmentDirect peers
- Syapse: Syapse operates a precision oncology platform that aggregates molecular and clinical data from health systems to enable therapy selection and real-world evidence. Comparable to Molecular Match on the data-driven therapy-selection and provider-side workflow axis.
- Massive Bio: Massive Bio provides AI-driven clinical trial matching and enrollment services for oncology patients, with pharma-sponsored enrollment support. Closely comparable as an AI clinical-trial-matching specialist competing for the same patient and pharma customers.
- Trialjectory: Trialjectory is an AI-powered clinical trial matching platform focused on oncology, using patient profiles and structured trial data to recommend trials. Directly comparable to Molecular Match as a standalone trial-matching platform, though Trialjectory emphasizes a patient-direct go-to-market.
- Caris Life Sciences: Caris offers molecular profiling (MI Profile) and a precision oncology platform that supports therapy selection and clinical trial matching across cancer types. Closely aligned with Molecular Match's molecular-matching value proposition and a likely direct competitor for the same hospital and pharma customers.
- Tempus: Tempus is an AI-driven precision medicine platform combining molecular profiling, clinical data structuring, and patient-to-trial matching for oncology. Closely comparable to Molecular Match in clinical trial enablement and therapy selection, but at vastly larger scale and with proprietary sequencing and data assets.
Broad incumbents
- IQVIA (including EDS/OCA Oncology): IQVIA operates large-scale clinical trial matching, site identification, and real-world oncology data capabilities through its E360 platform and EDS offerings. Comparable to Molecular Match on the trial-accrual and pharma-sponsor axis, though at enterprise scale.
- Flatiron Health: Flatiron Health (Roche subsidiary) operates an oncology-specific EHR and real-world data platform used by academic centers, community oncologists, and life sciences companies, with built-in clinical trial matching and molecular data integration. Directly comparable as a scaled precision-oncology workflow and trial-enablement competitor.
- Roche navify Clinical Hub: Roche's navify Clinical Hub bundles automated patient-to-trial screening, genomic profiling integration, MDT/tumor board workflows, and longitudinal disease management as an enterprise oncology platform. It is the most directly overlapping offering referenced in Molecular Match's market context and represents the scaled incumbent Molecular Match must either beat or integrate with.
- Foundation Medicine: Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling and a companion database that powers therapy selection and clinical trial matching for oncology patients. Comparable to Molecular Match on the therapy-selection and molecular-data side, but embedded within the Roche oncology diagnostics stack.
- Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company whose Guardant360 and related platforms support therapy selection and have growing clinical-trial-matching functionality. Comparable as a precision-oncology data and therapy-selection player, though at substantially greater scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Molecular Match social profiles
Digital presenceMolecular Match financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molecular Match leadership team
Management profileNumber of profiles
Profiles3 records
Molecular Match funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molecular Match M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molecular Match
What does Molecular Match do?
Molecular Match is a health and wellness company that develops technology for cancer treatment, leveraging molecular-level data to support treatment matching and decision-making. The company operates within the AI-driven genomics and precision medicine space, serving healthcare organizations involved in oncology care.
When was Molecular Match founded?
Molecular Match was founded in 2014. It employs 11 to 50 people.
Where is Molecular Match based?
Molecular Match is headquartered in Houston, United States, in the North America region.
Who are Molecular Match's main competitors?
Direct peers on record are Syapse, Massive Bio, Trialjectory, Caris Life Sciences and Tempus. Broad incumbents are IQVIA (including EDS/OCA Oncology), Flatiron Health, Roche navify Clinical Hub, Foundation Medicine and Guardant Health.
Does Molecular Match have an API?
No public API is recorded for Molecular Match.
What industry is Molecular Match in?
Molecular Match's product category is Precision Oncology Software. Its primary akta.pro industry code is HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials), with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 541714 and its SIC code is 2835.